The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL.
暂无分享，去创建一个
R. Norris | C. Dandoy | Erin H. Breese | B. Mizukawa | Stella M. Davies | Jeremy D. Rubinstein | M. C. Krupski | C. Phillips | R. Khoury | M. O’Brien | S. M. Davies | Ruby Khoury